1. Home
  2. News
  3. Imugene Ltd
  4. Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study
More Imugene Ltd news
Imugene LtdASX: IMU

Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study

Nov 1, 2023 at 10:59 PM EDT · Issued by Imugene Ltd

Filed with ASX · Nov 1, 2023 at 10:59 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/next-cohort-reached-in-iv-arms-of-cf33-hnis-vaxinia-study

Imugene Ltd on 6ix

Story so far

  • VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1Sep 4, 2023
  • Imugene VAXINIA Trial clears Cohort 3 of IT MonotherapyAug 14, 2023
  • Imugene Advances VAXINIA MAST Trial to Next IV CohortsJun 9, 2023

Earlier from Imugene

  • Imugene Phase 1 onCARlytics CD19 virus clinical trial opensOct 25, 2023
  • Imugene B Cell & OV Platforms Featured at ESMO CongressOct 23, 2023
  • Azer-cel FDA IND Transferred to ImugeneSep 27, 2023
  • Imugene Closes SPP Raising $18.2 millionSep 24, 2023
  • Imugene PD1-Vaxx UpdateSep 11, 2023

Later from Imugene

  • Phase 1 CF33 VAXINIA Study Update - Positive Early SignalsNov 5, 2023
  • Azer-cel Hits Major Milestone in Phase 1b CAR T TrialNov 9, 2023
  • FDA Fast Track Designation Granted for VAXINIA Trial ProgramNov 27, 2023
  • Imugene thrilled as VAXINIA granted FDA Fast Track designationNov 28, 2023
  • Europe Patent to be Granted for PD1-Vaxx Cancer VaccineDec 5, 2023
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer